Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33526211 | 0.93 | BTK (0.37) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL33525755 | 0.89 | KRAS (0.33) | KRAS | |
| SCHEMBL33526682 | 0.88 | KRAS (0.31) | KRAS | |
| SCHEMBL33525627 | 0.85 | GPR119 (0.33) | BTK | |
| SCHEMBL33526235 | 0.83 | KRAS (0.42) | BTKKRASCD69 | |
| SCHEMBL33526669 | 0.83 | PIK3CD (0.35) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL33526104 | 0.81 | BTK (0.35) | BTKPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL33525638 | 0.81 | BTK (0.30) | BTK | |
| SCHEMBL33527124 | 0.79 | KRAS (0.43) | BTKPIK3CDKRAS | |
| SCHEMBL33526366 | 0.79 | BTK (0.39) | BTKCD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | BTK 350/4885PIK3CD 266/4885PIK3CA 73/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | BTK 389/4885PIK3CD 249/4885PIK3CA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.